6NQ Stock Overview
A pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Synthaverse S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł0.87 |
| 52 Week High | zł1.28 |
| 52 Week Low | zł0.63 |
| Beta | 1.2 |
| 1 Month Change | 3.45% |
| 3 Month Change | -9.84% |
| 1 Year Change | 0.12% |
| 3 Year Change | -11.68% |
| 5 Year Change | n/a |
| Change since IPO | -80.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6NQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.2% | 3.1% | 0.5% |
| 1Y | 0.1% | -13.8% | 7.2% |
Return vs Industry: 6NQ exceeded the German Biotechs industry which returned -14.5% over the past year.
Return vs Market: 6NQ underperformed the German Market which returned 7% over the past year.
Price Volatility
| 6NQ volatility | |
|---|---|
| 6NQ Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6NQ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6NQ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 239 | Mieczyslaw Starkowicz | www.synthaverse.pl |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal products, medical devices, and laboratory reagents in Poland. The company’s prescription drugs include Distreptaza, a medication used in gynecology for treating chronic inflammatory disease of the uterine appendages and hemorrhoids; Onko BCG 50 and BCG 100 products for treating superficial (non-muscle invasive) bladder tumor; GAMMA anty HBs 200 medications for passive immunization against hepatitis B; GAMMA anty-D 50 and GAMMA anty-D 150, which are Anti D (Rho) immunoglobulin products used in prevention of hemolytic disease of the foetus and newborn; BioTrombina 400, a medication for topical control of severe bleeding; and Anti-Tuberculosis Vaccine BCG 10, a medication used in tuberculosis prevention. It also offers medical products comprising Ram blood for laboratory use; stonebrink medium for biovine Mycobacterium tuberculosis diagnostics; Löwenstein-Jensen medium with medicines for testing medicine susceptibility of Mycobacterium tuberculosis; Löwenstein-Jensen medium containing glycerolfor is used for identification of Mycobacterium tuberculosis; Ox Thrombin for in-vitro diagnostics and Lyophilisate; and rabbit plasma.
Synthaverse S.A. Fundamentals Summary
| 6NQ fundamental statistics | |
|---|---|
| Market cap | €72.47m |
| Earnings (TTM) | €1.04m |
| Revenue (TTM) | €14.67m |
69.6x
P/E Ratio4.9x
P/S RatioIs 6NQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6NQ income statement (TTM) | |
|---|---|
| Revenue | zł62.66m |
| Cost of Revenue | zł24.58m |
| Gross Profit | zł38.08m |
| Other Expenses | zł33.63m |
| Earnings | zł4.45m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.063 |
| Gross Margin | 60.77% |
| Net Profit Margin | 7.10% |
| Debt/Equity Ratio | 71.9% |
How did 6NQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 17:30 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Synthaverse S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|